CytomX Announces Conference Call and Webcast to Review PROCLAIM-072 Clinical Data Presentations at the 2018 American Society ...
01 Junio 2018 - 6:30AM
CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody™
therapeutic technology platform, today announced that it will host
a conference call and live webcast on Monday, June 4th at 5:00 p.m.
CT/ 6:00 p.m. ET to discuss presentations of preliminary clinical
results from PROCLAIM-072, an ongoing Phase 1/2 trial evaluating
CX-072, a Probody therapeutic targeting PD-L1, at the 2018 Annual
Meeting of the American Society of Clinical Oncology (ASCO).
Conference call and webcast details are as follows:
Date and Time:
- Monday, June 4, 2018
- 5:00 p.m. Central Time/ 6:00 p.m. Eastern Time
Audio Conference Call:
- U.S. Toll Free Dial-in Number: (877) 809-6037
- International Dial-in Number: (615) 247-0221
- Conference ID: 4294667
Live Webcast:
- Access the Events and Presentations Section of CytomX’s
Investor Relations section at
http://ir.cytomx.com/events-and-presentations
- Access the website 15 minutes prior to the start of the call to
download and install any necessary audio software with slides
Replay:
- A replay of the webcast will be archived and available on
CytomX’s website for three months following the event.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage oncology-focused
biopharmaceutical company pioneering a novel class of
investigational antibody therapeutics based on its Probody
therapeutic technology platform. Probody therapeutics are designed
to exploit unique conditions of the tumor microenvironment to more
effectively localize antibody binding and activity while limiting
activity in healthy tissues. The Company’s pipeline includes cancer
immunotherapies against clinically-validated potential targets,
such as CX-072, a PD-L1-targeting Probody therapeutic wholly-owned
by CytomX, BMS-986249, a CTLA-4-targeting Probody therapeutic
partnered with Bristol Myers Squibb, CX-188, a PD-1-targeting
Probody therapeutic wholly-owned by CytomX, and first-in-class
Probody drug conjugates against high potential targets, such as
CX-2009, a CD166-targeting Probody drug conjugate wholly-owned by
CytomX and CX-2029, a CD71-targeting Probody drug conjugate
partnered with AbbVie, which are considered to be inaccessible to
conventional antibody drug conjugates due to their presence on
healthy tissue. In addition to its wholly owned programs, CytomX
has strategic collaborations with AbbVie, Amgen, Bristol-Myers
Squibb Company, and ImmunoGen, Inc. For more information, visit
www.cytomx.com or follow us on Twitter.
CytomX Therapeutics
Investors:
Christopher Keenan VP, Investor Relations and Corporate
Communications ckeenan@cytomx.com 650-383-0823
Media:
Spectrum Christine Quern cquern@spectrumscience.com
202-587-2588
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024